- Home
- NXTC vs RAPT Comparison
NXTC vs RAPT Comparison
Compare NXTC & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- RAPT
- Stock Information
- Founded
- NXTC 2015
- RAPT 2015
- Country
- NXTC United States
- RAPT United States
- Employees
- NXTC N/A
- RAPT N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- RAPT Health Care
- Exchange
- NXTC Nasdaq
- RAPT Nasdaq
- Market Cap
- NXTC 31.6M
- RAPT 30.8M
- IPO Year
- NXTC 2019
- RAPT 2019
- Fundamental
- Price
- NXTC $0.89
- RAPT $0.89
- Analyst Decision
- NXTC Strong Buy
- RAPT Hold
- Analyst Count
- NXTC 2
- RAPT 10
- Target Price
- NXTC $4.00
- RAPT $5.00
- AVG Volume (30 Days)
- NXTC 218.5K
- RAPT 386.3K
- Earning Date
- NXTC 11-07-2024
- RAPT 11-12-2024
- Dividend Yield
- NXTC N/A
- RAPT N/A
- EPS Growth
- NXTC N/A
- RAPT N/A
- EPS
- NXTC N/A
- RAPT N/A
- Revenue
- NXTC N/A
- RAPT N/A
- Revenue This Year
- NXTC N/A
- RAPT N/A
- Revenue Next Year
- NXTC N/A
- RAPT N/A
- P/E Ratio
- NXTC N/A
- RAPT N/A
- Revenue Growth
- NXTC N/A
- RAPT N/A
- 52 Week Low
- NXTC $0.87
- RAPT $0.81
- 52 Week High
- NXTC $2.57
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- NXTC 22.88
- RAPT 36.23
- Support Level
- NXTC $1.06
- RAPT $0.84
- Resistance Level
- NXTC $1.21
- RAPT $1.18
- Average True Range (ATR)
- NXTC 0.10
- RAPT 0.10
- MACD
- NXTC -0.02
- RAPT 0.01
- Stochastic Oscillator
- NXTC 5.21
- RAPT 17.00
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.